ストックスクリーナーアプリを入手
2.68
1.47%
-0.04
プレマーケット:
2.71
0.03
+1.12%
前日終値:
$2.72
開ける：
$2.72
24時間の取引高:
1.02M
Relative Volume:
0.87
時価総額：
$217.78M
収益：
-
当期純損益:
$-78.15M
株価収益率:
-3.1261
EPS:
-0.8573
ネットキャッシュフロー:
$-68.89M
1週間 パフォーマンス:
+1.13%
1か月 パフォーマンス:
-21.41%
6か月 パフォーマンス:
-7.27%
1年 パフォーマンス:
+10.74%
1日の値動き範囲:
$2.60
$2.771
1週間の範囲:
$2.57
$3.09
52週間の値動き範囲:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
名前
Eledon Pharmaceuticals Inc
セクター
電話
949-238-8090
住所
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.68 | 217.78M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Guggenheim | Buy |
| 2022-05-13 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 開始されました | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026Slideshow (NASDAQ:ELDN) 2026-09-22 - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Shares Rise on Positive Tegoprubar - GuruFocus
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) - Seeking Alpha
Eledon Gains 13% on Updated Phase 2 Trial Data - Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Advances Tegoprubart Trials with F - GuruFocus
Eledon Pharmaceuticals, Inc. (ELDN) stock price, news, quote and history - uk.finance.yahoo.com
Eledon’s tegoprubart shows kidney function advantage in phase 2 trial - Investing.com
Eledon’s tegoprubart shows kidney function advantage in phase 2 trial By Investing.com - Investing.com Nigeria
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
ELDN Should I Buy - Intellectia AI
A treatment to prevent kidney transplant rejection will be presented Sept. 22 - Stock Titan
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - The Manila Times
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart - marketscreener.com
Eledon submits IND for tegoprubart islet cell transplant study - investing.com
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceNAAIM Leverage - dars.gov.et
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureMerger Arbitrage - vinanet.vn
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - vinanet.vn
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - vinanet.vn
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - vinanet.vn
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEPS Surprise History - careplusvn.com
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsMoving Average Ribbon - careplusvn.com
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock Declines - dars.gov.et
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADAR1 Capital Management LLC Has $3 Million Position in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Cash Flow - TradingKey
Eledon Pharmaceuticals rated Buy as tegoprubart shows promise in kidney transplant treatment and undervaluation. - Pluang
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - webull.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon Pharmaceuticals Inc (ELDN) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):